12-Jul-2022

Kazia Therapeutics forms new Scientific Advisory Board with world-leading experts in brain cancer

Kazia has launched a new Scientific Advisory Board (SAB) consisting of four distinguished clinicians and scientists with expertise in the development of innovative therapies for brain cancer.

07-Jul-2022

Kazia Therapeutics gains US FDA Rare Paediatric Disease Designation for paxalisib in rare form of childhood brain cancer

Kazia has been awarded a Rare Paediatric Disease Designation (RPDD) by the US Food and Drug Administration (FDA) for the use of paxalisib in the treatment of atypical rhabdoid/teratoid tumours (AT/RT), a rare and highly aggressive childhood brain cancer.

06-Jul-2022

Stocks of the Hour: Elsight, Kazia Therapeutics, Chalice Mining

The US FDA has awarded Kazia Therapeutics (ASX:KZA) a designation for its treatment for rare brain cancer in children. 

06-Jul-2022

V-Con: Small Cap Showcase - Kazia Interview and Presentation